Postoperative Pain Management Market

1. Executive Summary
     1.1. Market Overview
     1.2. Market Analysis
     1.3. PMR Analysis and Recommendations
     1.4. Wheel of Fortune

2. Market Introduction
     2.1. Market Definition
     2.2. Market Taxonomy

3. Postoperative Pain Management Market Opportunity Analysis
     3.1. Macro-Economic Factors
     3.2. Opportunity Analysis

4. Market Background
     4.1. Market Dynamics
            4.1.1. Drivers
            4.1.2. Restraints
            4.1.3. Trends
     4.2. Regulatory Scenario

5. Global Economic Outlook
     5.1. Gross Domestic Product by Region & Country, 2006 – 2021
     5.2. Global Healthcare Market Outlook

6. Key Inclusions
     6.1. Key Distributors List

7. North America Postoperative Pain Management Market Analysis 2013–2017 and Forecast 2018–2026
     7.1. Introduction
     7.2. Historical Market Size (US$ Mn) Analysis By Country, 2013–2017
            7.2.1. U.S.
            7.2.2. Canada
     7.3. Market Size (US$ Mn) Forecast By Coun
     7.4. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
            7.4.1. Opioids
            7.4.2. NSAIDS
            7.4.3. Local Anaesthetics
            7.4.4. Acetaminophen
     7.5. Market Size (US$ Mn) Forecast By Drug Class, 2018–2026
     7.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
            7.6.1. Injectable
            7.6.2. Oral
            7.6.3. Topical
            7.6.4. Transdermal
            7.6.5. Others
     7.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2026
     7.8. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
            7.8.1. Hospital Pharmacies
            7.8.2. Retail Pharmacies
            7.8.3. Drug Store
            7.8.4. Clinics
            7.8.5. Others
     7.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
     7.10.Market Attractiveness Analysis
            7.10.1. By Country
            7.10.2. By Drug Class
            7.10.3. By Route of Administration
            7.10.4. By Distribution Channel
     7.11.Key Market Participants – Intensity Mapping
     7.12.Drivers and Restraints – Impact Analysis

8. Latin America Postoperative Pain Management Market Analysis 2013–2017 and Forecast 2018–2026
     8.1. Introduction
     8.2. Historical Market Size (US$ Mn) Trends Analysis By Country, 2012–2016
            8.2.1. Brazil
            8.2.2. Mexico
            8.2.3. Rest of Latin America
     8.3. Market Size (US$ Mn) Forecast By Country, 2018–2026
     8.4. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
            8.4.1. Opioids
            8.4.2. NSAIDS
            8.4.3. Local Anaesthetics
            8.4.4. Acetaminophen
     8.5. Market Size (US$ Mn) Forecast By Drug Class, 2018–2026
     8.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
            8.6.1. Injectables
            8.6.2. Oral
            8.6.3. Topical
            8.6.4. Transdermal
            8.6.5. Others
     8.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2026
     8.8. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
            8.8.1. Hospital Pharmacies
            8.8.2. Retail Pharmacies
            8.8.3. Drug Store
            8.8.4. Clinics
            8.8.5. Others
     8.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
     8.10.Market Attractiveness Analysis
            8.10.1. By Country
            8.10.2. By Drug Class
            8.10.3. By Route of Administration
            8.10.4. By Distribution Channel
     8.11.Key Market Participants – Intensity Mapping
     8.12.Drivers and Restraints – Impact Analysis

9. Europe Postoperative Pain Management Market Analysis 2013–2017 and Forecast 2018–2026
     9.1. Introduction
     9.2. Regional Market Trends
     9.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
            9.3.1. U.K.
            9.3.2. Germany
            9.3.3. France
            9.3.4. Italy
            9.3.5. Spain
            9.3.6. Russia
            9.3.7. Rest of Europe
     9.4. Market Size (US$ Mn) Forecast By Country, 2018–2026
     9.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
            9.5.1. Opioids
            9.5.2. NSAIDS
            9.5.3. Local Anaesthetics
            9.5.4. Acetaminophen
     9.6. Market Size (US$ Mn) Forecast By Drug Class, 2018–2026
     9.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
            9.7.1. Injectables
            9.7.2. Oral
            9.7.3. Topical
            9.7.4. Transdermal
            9.7.5. Others
     9.8. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2026
     9.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
            9.9.1. Hospital Pharmacies
            9.9.2. Retail Pharmacies
            9.9.3. Drug Store
            9.9.4. Clinics
            9.9.5. Others
     9.10.Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
     9.11.Market Attractiveness Analysis
            9.11.1. By Country
            9.11.2. By Drug Class
            9.11.3. By Route of Administration
            9.11.4. By Distribution Channel
     9.12.Key Market Participants – Intensity Mapping
     9.13.Drivers and Restraints – Impact Analysis

10. Asia Pacific Excluding China Postoperative Pain Management Market Analysis 2013–2017 and Forecast 2018–2026
     10.1.Introduction
     10.2.Regional Market Trends
     10.3.Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
            10.3.1. Japan
            10.3.2. India
            10.3.3. Australia and New Zealand
            10.3.4. ASEAN
            10.3.5. Rest of Asia Pacific
     10.4.Market Size (US$ Mn) Forecast By Country, 2018–2026
     10.5.Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
            10.5.1. Opioids
            10.5.2. NSAIDS
            10.5.3. Local Anaesthetics
            10.5.4. Acetaminophen
     10.6.Market Size (US$ Mn) Forecast By Drug Class, 2018–2026
     10.7.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
            10.7.1. Injectables
            10.7.2. Oral
            10.7.3. Topical
            10.7.4. Transdermal
            10.7.5. Others
     10.8.Market Size (US$ Mn) Forecast By Route of Administration, 2018-2026
     10.9.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
            10.9.1. Hospital Pharmacies
            10.9.2. Retail Pharmacies
            10.9.3. Drug Store
            10.9.4. Clinics
            10.9.5. Others
     10.10.Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
     10.11.Market Attractiveness Analysis
            10.11.1. By Country
            10.11.2. By Drug Class
            10.11.3. By Route of Administration
            10.11.4. By Distribution Channel
     10.12. Key Market Participants – Intensity Mapping
     10.13. Drivers and Restraints – Impact Analysis

11. China Postoperative Pain Management Market Analysis 2013–2017 and Forecast 2018–2026
     11.1.Introduction
     11.2.Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
            11.2.1. Opioids
            11.2.2. NSAIDS
            11.2.3. Local Anaesthetics
            11.2.4. Acetaminophen
     11.3.Market Size (US$ Mn) Forecast By Drug Class, 2018–2026
     11.4.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
            11.4.1. Injectables
            11.4.2. Oral
            11.4.3. Topical
            11.4.4. Transdermal
            11.4.5. Others
     11.5.Market Size (US$ Mn) Forecast By Route of Administration, 2018-2026
     11.6.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
            11.6.1. Hospital Pharmacies
            11.6.2. Retail Pharmacies
            11.6.3. Drug Store
            11.6.4. Clinics
            11.6.5. Others
     11.7.Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
     11.8.Market Attractiveness Analysis
            11.8.1. By Drug Class
            11.8.2. By Route of Administration
            11.8.3. By Distribution Channel
     11.9.Key Market Participants – Intensity Mapping
     11.10. Drivers and Restraints – Impact Analysis

12. Middle East & Africa Postoperative Pain Management Market Analysis 2013–2017 and Forecast 2018–2026
     12.1.Introduction
     12.2.Regional Market Trends
     12.3.Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
            12.3.1. South Africa
            12.3.2. GCC Countries
            12.3.3. Rest of MEA
     12.4.Market Size (US$ Mn) Forecast By Country, 2018–2026
     12.5.Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
            12.5.1. Opioids
            12.5.2. NSAIDS
            12.5.3. Local Anaesthetics
            12.5.4. Acetaminophen
     12.6.Market Size (US$ Mn) Forecast By Drug Class, 2018–2026
     12.7.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
            12.7.1. Injectables
            12.7.2. Oral
            12.7.3. Topical
            12.7.4. Transdermal
            12.7.5. Others
     12.8.Market Size (US$ Mn) Forecast By Route of Administration, 2018-2026
     12.9.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
            12.9.1. Hospital Pharmacies
            12.9.2. Retail Pharmacies
            12.9.3. Drug Store
            12.9.4. Clinics
            12.9.5. Others
     12.10.Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
     12.11.Market Attractiveness Analysis
            12.11.1. By Country
            12.11.2. By Drug Class
            12.11.3. By Route of Administration
            12.11.4. By Distribution Channel
     12.12. Key Market Participants – Intensity Mapping
     12.13. Drivers and Restraints – Impact Analysis

13. Forecast Factors: Relevance and Impact

14. Forecast Assumptions

15. Market Structure Analysis
     15.1.Market Structure Analysis by Tier
     15.2.Company Share Analysis (2017)

16. Competition Landscape
     16.1.Market Structure Analysis
     16.2.Competition Dashboard
     16.3.Competition Benchmarking
     16.4.Company Deep Dive
            16.4.1. Teva Pharmaceutical Industries Ltd.
                    16.4.1.1. Overview
                    16.4.1.2. Product and Application Portfolio
                    16.4.1.3. Production Footprint
                    16.4.1.4. Sales Footprint
                    16.4.1.5. Channel Footprint
                    16.4.1.6. Strategy
                                   16.4.1.6.1. Marketing Strategy
                                   16.4.1.6.2. Product Strategy
                                   16.4.1.6.3. Channel Strategy
            16.4.2. Novartis AG
                    16.4.2.1. Overview
                    16.4.2.2. Product and Application Portfolio
                    16.4.2.3. Production Footprint
                    16.4.2.4. Sales Footprint
                    16.4.2.5. Channel Footprint
                    16.4.2.6. Strategy
                                   16.4.2.6.1. Marketing Strategy
                                   16.4.2.6.2. Product Strategy
                                   16.4.2.6.3. Channel Strategy
            16.4.3. Allergan plc
                    16.4.3.1. Overview
                    16.4.3.2. Product and Application Portfolio
                    16.4.3.3. Production Footprint
                    16.4.3.4. Sales Footprint
                    16.4.3.5. Channel Footprint
                    16.4.3.6. Strategy
                                   16.4.3.6.1. Marketing Strategy
                                   16.4.3.6.2. Product Strategy
                                   16.4.3.6.3. Channel Strategy
            16.4.4. Mylan N.V.
                    16.4.4.1. Overview
                    16.4.4.2. Product and Application Portfolio
                    16.4.4.3. Production Footprint
                    16.4.4.4. Sales Footprint
                    16.4.4.5. Channel Footprint
                    16.4.4.6. Strategy
                                   16.4.4.6.1. Marketing Strategy
                                   16.4.4.6.2. Product Strategy
                                   16.4.4.6.3. Channel Strategy
            16.4.5. Pfizer Inc.
                    16.4.5.1. Overview
                    16.4.5.2. Product and Application Portfolio
                    16.4.5.3. Production Footprint
                    16.4.5.4. Sales Footprint
                    16.4.5.5. Channel Footprint
                    16.4.5.6. Strategy
                                   16.4.5.6.1. Marketing Strategy
                                   16.4.5.6.2. Product Strategy
                                   16.4.5.6.3. Channel Strategy
            16.4.6. Purdue Pharma L.P
                    16.4.6.1. Overview
                    16.4.6.2. Product and Application Portfolio
                    16.4.6.3. Production Footprint
                    16.4.6.4. Sales Footprint
                    16.4.6.5. Channel Footprint
                    16.4.6.6. Strategy
                                   16.4.6.6.1. Marketing Strategy
                                   16.4.6.6.2. Product Strategy
                                   16.4.6.6.3. Channel Strategy
            16.4.7. Janssen Pharmaceuticals, Inc.
                    16.4.7.1. Overview
                    16.4.7.2. Product and Application Portfolio
                    16.4.7.3. Production Footprint
                    16.4.7.4. Sales Footprint
                    16.4.7.5. Channel Footprint
                    16.4.7.6. Strategy
                                   16.4.7.6.1. Marketing Strategy
                                   16.4.7.6.2. Product Strategy
                                   16.4.7.6.3. Channel Strategy
            16.4.8. Endo International plc
                    16.4.8.1. Overview
                    16.4.8.2. Product and Application Portfolio
                    16.4.8.3. Production Footprint
                    16.4.8.4. Sales Footprint
                    16.4.8.5. Channel Footprint
                    16.4.8.6. Strategy
                                   16.4.8.6.1. Marketing Strategy
                                   16.4.8.6.2. Product Strategy
                                   16.4.8.6.3. Channel Strategy
            16.4.9. Pacira Pharmaceuticals Inc.
                    16.4.9.1. Overview
                    16.4.9.2. Product and Application Portfolio
                    16.4.9.3. Production Footprint
                    16.4.9.4. Sales Footprint
                    16.4.9.5. Channel Footprint
                    16.4.9.6. Strategy
                                   16.4.9.6.1. Marketing Strategy
                                   16.4.9.6.2. Product Strategy
                                   16.4.9.6.3. Channel Strategy
            16.4.10. Egalet Corporation
                    16.4.10.1. Overview
                    16.4.10.2. Product and Application Portfolio
                    16.4.10.3. Production Footprint
                    16.4.10.4. Sales Footprint
                    16.4.10.5. Channel Footprint
                    16.4.10.6. Strategy
                                   16.4.10.6.1. Marketing Strategy
                                   16.4.10.6.2. Product Strategy
                                   16.4.10.6.3. Channel Strategy
            16.4.11. GlaxoSmithKline Plc.
                    16.4.11.1. Overview
                    16.4.11.2. Product and Application Portfolio
                    16.4.11.3. Production Footprint
                    16.4.11.4. Sales Footprint
                    16.4.11.5. Channel Footprint
                    16.4.11.6. Strategy
                                   16.4.11.6.1. Marketing Strategy
                                   16.4.11.6.2. Product Strategy
                                   16.4.11.6.3. Channel Strategy

17. Global Postoperative Pain Management Market Analysis 2013–2017 and Forecast 2018–2026, By Region
     17.1.Introduction/Key Findings
     17.2.Historical Market Size (US$ Mn) Analysis By Region, 2013–2017
     17.3.Market Size (US$ Mn) Forecast By Region, 2018–2026
            17.3.1. North America
            17.3.2. Latin America
            17.3.3. Europe
            17.3.4. Asia Pacific excluding China
            17.3.5. China
            17.3.6. Middle East & Africa
     17.4.Market Attractiveness Analysis By Region

18. Global Postoperative Pain Management Analysis 2013–2017 and Forecast 2018–2026, By Drug Class
     18.1.Introduction/Key Findings
     18.2.Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017
            18.2.1. NSAIDS
            18.2.2. Opioids
            18.2.3. Local Anaesthetics
            18.2.4. Acetaminophen
     18.3.Market Size (US$ Mn) Forecast By Drug Class, 2018–2026
     18.4.Market Attractiveness Analysis By Drug Class

19. Global Postoperative Pain Management Market Analysis 2013–2017 and Forecast 2018–2026, By Route of Administration
     19.1.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
            19.1.1. Injectables
            19.1.2. Oral
            19.1.3. Topical
            19.1.4. Transdermal
            19.1.5. Others
     19.2.Market Size (US$ Mn) Forecast By Route of Administration, 2018-2026
     19.3.Market Attractiveness Analysis By Route of Administration

20. Global Postoperative Pain Management Market Analysis 2013–2017 and Forecast 2018–2026, By Distribution Channel
     20.1.Introduction/Key Findings
     20.2.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017
            20.2.1. Hospital Pharmacies
            20.2.2. Retail Pharmacies
            20.2.3. Drug Store
            20.2.4. Clinics
            20.2.5. Others
     20.3.Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
     20.4.Market Attractiveness Analysis By Distribution Channel

21. Global Postoperative Pain Management Market Analysis 2013–2017 and Forecast 2018–2026
     21.1.Market Value Projections
     21.2.Y-o-Y Growth Analysis
     21.3.Absolute $ Opportunity

22. Research Methodology